Earnings summaries and quarterly performance for Wave Life Sciences.
Executive leadership at Wave Life Sciences.
Board of directors at Wave Life Sciences.
Research analysts who have asked questions during Wave Life Sciences earnings calls.
Catherine Novack
JonesTrading Institutional Services LLC
4 questions for WVE
Also covers: ALDX, CAPR, CRNX +3 more
JL
Joon Lee
Truist Securities
4 questions for WVE
Also covers: ADVM, AXSM, CNM +14 more
MW
Madison Wynne El-Saadi
B. Riley Securities
4 questions for WVE
Also covers: AGEN, CAPR, ETON +1 more
SS
Salim Syed
Mizuho Securities
4 questions for WVE
Also covers: AUTL, BBIO, CYTK +5 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for WVE
Also covers: ACRS, CRVS, CTMX +12 more
JS
Joseph Schwartz
Oppenheimer
2 questions for WVE
Also covers: ASND, AUPH, BMRN +14 more
LW
Lisa Walter
RBC Capital Markets
2 questions for WVE
Also covers: APLS, EYPT, OCUL +2 more
RF
Ron Feiner
Leerink Partners
2 questions for WVE
Also covers: KYMR
Ananda Ghosh
H.C. Wainwright & Co.
1 question for WVE
Also covers: ABOS, ALEC, AMLX +1 more
AF
Andrew Fein
H.C. Wainwright & Co.
1 question for WVE
Anthony
Raymond James
1 question for WVE
Also covers: AB, COO, TRVI
Cheng Li
Oppenheimer & Co. Inc.
1 question for WVE
Also covers: EDIT, EXEL, INO +3 more
Eric Joseph
JPMorgan Chase & Co.
1 question for WVE
Also covers: BEAM, BLUE, ENTA +9 more
Jenny Leigh Gonzalez-Armenta
Leerink Partners
1 question for WVE
Also covers: QURE
JS
Joe Schwartz
Leerink Partners
1 question for WVE
Also covers: BMRN, KALV, PTGX
LI
Luca Issi
RBC Capital Markets
1 question for WVE
Also covers: ADVM, ALLO, ALNY +12 more
Martin Auster
Raymond James
1 question for WVE
NE
Nicholas Econom
Raymond James
1 question for WVE
Also covers: APLS, EDIT
RS
Roger Song
Jefferies
1 question for WVE
Also covers: AADI, AKBA, ALT +13 more
Ryan Deschner
Raymond James Financial
1 question for WVE
Also covers: APLS, ARDX, ARSP +7 more
Samantha Semenkow
Citigroup Inc.
1 question for WVE
Also covers: ALLO, ARGX, BEAM +7 more
SS
Steven Seedhouse
Raymond James
1 question for WVE
Also covers: APLS, BCRX, EDIT +2 more
Steve Seedhouse
Cantor Fitzgerald
1 question for WVE
Also covers: BCRX, BOLD, HROW +1 more
TF
Tiago Fauth
Wells Fargo
1 question for WVE
Also covers: LQDA, PTCT, VRNA
YJ
Yun Jung
Wedbush Securities
1 question for WVE
Yun Zhong
Wedbush Securities
1 question for WVE
Also covers: ASND, MNKD, MRKR +2 more
Recent press releases and 8-K filings for WVE.
Wave Life Sciences Presents 2026 Strategic Focus and Clinical Program Updates at J.P. Morgan Healthcare Conference
WVE
New Projects/Investments
Guidance Update
- Wave Life Sciences entered 2026 with $602 million of cash, which is projected to fund operations into the third quarter of 2028.
- The company's strategic focus for 2026 includes accelerating the development of WVE-007 for obesity and advancing its RNA editing portfolio, specifically WVE-006 for AATD and WVE-008 for PNPLA3.
- For WVE-007, the company announced moving to the Phase 2A portion of the INLIGHT study and plans to initiate new clinical studies for combination, add-on, and maintenance treatments this year. Phase 1 data showed a 9.5% reduction in visceral fat and preservation of muscle mass.
- Key data milestones anticipated for Q1 2026 include the 400 mg three-month data and 240 mg six-month data for WVE-007, as well as the 400 mg data for WVE-006.
- Wave Life Sciences expects to submit the NDA for N531 in 2026 but will seek commercial distribution partners rather than investing its own capital.
1 day ago
Wave Life Sciences Outlines 2026 Strategic Focus and Financial Position
WVE
Guidance Update
New Projects/Investments
- Wave Life Sciences reported a cash position of $602 million at the start of 2026, providing a runway into the third quarter of 2028.
- The company's strategic focus for 2026 includes accelerating the WVE-007 program for obesity, which demonstrated a 9.5% reduction in visceral fat and muscle preservation in Phase I, and is progressing to Phase 2a.
- Wave is also advancing its RNA editing portfolio, with WVE-006 for AATD expected to release 400-milligram multidose data in Q1 2026, and WVE-008 for PNPLA3 slated to enter the clinic.
1 day ago
Wave Life Sciences Outlines Strategic Focus for 2026 and Provides Pipeline Updates
WVE
New Projects/Investments
Guidance Update
- Wave Life Sciences entered 2026 with $602 million of cash, which is projected to provide a cash runway into the third quarter of 2028.
- The company's strategic focus for 2026 is on accelerating the development of WVE-007, their GalNAc-conjugated INHBE siRNA program for obesity, by moving to the Phase 2A portion of the INLIGHT study and initiating new clinical studies for combination, add-on, and maintenance therapies.
- Clinical data for WVE-007 demonstrated a 9.5% reduction in visceral fat and a substantial reduction in total fat mass, while preserving lean mass, with the potential for once to twice-a-year dosing.
- Wave is also advancing its RNA editing portfolio, with WVE-006 for AATD expecting 400-milligram data in Q1 2026, and WVE-008 for PNPLA3 (liver disease) transitioning into the clinic with a CTA filing anticipated in 2026.
- The company plans to submit the NDA for N531 in 2026 but will seek commercial distribution partners for it, rather than investing its own capital.
1 day ago
Wave Life Sciences Details Pipeline Progress and Financial Position
WVE
New Projects/Investments
Guidance Update
Product Launch
- Wave Life Sciences reported preliminary, unaudited cash and cash equivalents of ~$602 million as of December 31, 2025, with an expected cash runway into 3Q 2028.
- The company's strategic focus for 2026 is to accelerate the development of WVE-007 (obesity) and advance its RNA editing portfolio, including WVE-006 (AATD) and WVE-008 (liver disease).
- Upcoming milestones in 1Q 2026 include delivering 3-month 400 mg and 6-month 240 mg data for WVE-007, and 400 mg multidose cohort data for WVE-006.
- In 1H 2026, the company plans to initiate the Phase 2a multidose portion of the INLIGHT trial for WVE-007.
- Additional 2026 milestones include delivering 600 mg cohort data for WVE-006, filing a CTA for WVE-008, and submitting an NDA for WVE-N531 (DMD) to support accelerated approval.
1 day ago
Wave Life Sciences Highlights 2026 Strategic Priorities and Financial Position
WVE
New Projects/Investments
Guidance Update
- Wave Life Sciences is accelerating the development of WVE-007 for obesity, with plans to initiate a Phase 2a multidose clinical trial in 1H 2026 and new trials for add-on and post-incretin maintenance in 2026.
- The company expects to deliver several data updates for WVE-007 in Q1 and Q2 2026, including six-month 240 mg data and three-month 400 mg data in Q1, and six-month 400 mg data and three-month 600 mg data in Q2.
- Key milestones for the RNA editing portfolio include multiple data updates for WVE-006 (AATD) in 2026 and a Clinical Trial Application (CTA) filing for WVE-008 (liver disease) in 2026.
- Wave Life Sciences plans to submit a New Drug Application (NDA) in 2026 for accelerated approval of WVE-N531 for Duchenne muscular dystrophy (DMD).
- The company reported preliminary, unaudited cash and cash equivalents of ~$602 million as of December 31, 2025, with an expected cash runway into 3Q 2028.
3 days ago
Wave Life Sciences Ltd. Announces Upsized Public Offering and Cash Runway Update
WVE
Guidance Update
New Projects/Investments
- Wave Life Sciences Ltd. priced an upsized public offering of 15,789,475 ordinary shares at $19.00 per share and 2,631,578 pre-funded warrants at $18.9999 per pre-funded warrant.
- The underwriters fully exercised their option to purchase an additional 2,763,157 ordinary shares on December 10, 2025.
- Gross proceeds from the offering are expected to be approximately $402.5 million, including the full exercise of the underwriters' option.
- The offering is expected to close on or about December 11, 2025.
- Following the closing, the company expects to have approximately 187,693,059 ordinary shares outstanding and its current cash and cash equivalents will be sufficient to fund operations into the third quarter of 2028.
Dec 11, 2025, 2:47 AM
Wave Life Sciences Prices Public Offering
WVE
- Wave Life Sciences announced the pricing of an underwritten public offering of ordinary shares and pre-funded warrants on December 9, 2025.
- The offering includes 15,789,475 ordinary shares at $19.00 per share and 2,631,578 pre-funded warrants at $18.9999 per warrant.
- The company expects to receive approximately $350 million in gross proceeds from the offering.
- The offering is anticipated to close on or about December 11, 2025.
Dec 10, 2025, 2:50 AM
Wave Life Sciences Announces Proposed Public Offering
WVE
- Wave Life Sciences (Nasdaq: WVE) has commenced an underwritten public offering to raise $250 million in aggregate through the sale of its ordinary shares and pre-funded warrants.
- The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold.
- Jefferies, Leerink Partners, and BofA Securities are acting as joint book-running managers for the offering.
- The offering is subject to market and other conditions, with no assurance as to its completion, actual size, or terms.
Dec 8, 2025, 9:01 PM
Wave Life Sciences Reports Positive Interim Clinical Data for WVE-007 in Obesity
WVE
New Projects/Investments
- Wave Life Sciences announced positive interim clinical data from its Phase 1 INLIGHT trial of WVE-007 for obesity.
- A single 240 mg dose of WVE-007 led to improved body composition at three months, including a 4.5% reduction in total body fat and a 9.4% reduction in visceral fat, while preserving muscle mass with a 3.2% increase in lean mass.
- The treatment was generally safe and well tolerated through 600 mg, with no serious adverse events or discontinuations reported.
- The company is planning Phase 2 trials for WVE-007 across multiple treatment settings, including monotherapy and as an add-on to incretin treatments.
- Further data updates are anticipated in 1Q26, including 6-month follow-up from the 240 mg cohort and 3-month follow-up from the 400 mg cohort.
Dec 8, 2025, 1:30 PM
Wave Life Sciences Announces Positive Interim Clinical Data for WVE-007
WVE
New Projects/Investments
- Wave Life Sciences reported positive interim clinical data from its ongoing Phase 1 IN-LIGHT trial of WVE-007, an inhibin E GalNAc siRNA, in individuals living with overweight or obesity.
- After three months, a single dose of WVE-007 (240mg cohort) led to a 4.5% reduction in total body fat, a 9.4% reduction in visceral fat, and a 3.2% increase in lean mass. These improvements in body composition were observed in participants without diet or exercise modifications.
- The trial demonstrated a favorable safety profile for WVE-007, with no discontinuations, serious treatment-emergent adverse events (TEAEs), or deaths through the 600mg cohort, and all drug-related AEs were mild.
- WVE-007 achieved total fat reductions comparable to semaglutide at 12 weeks, while preserving lean mass and driving greater reductions in visceral fat, supporting a convenient once or twice yearly dosing interval.
- The company anticipates releasing six-month follow-up data from the 240mg cohort and three-month data from the 400mg cohort in the next quarter, with further data from higher doses and longer durations expected in Q2 2026.
Dec 8, 2025, 1:30 PM
Quarterly earnings call transcripts for Wave Life Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more